Buzz Stocks: Twitter Inc, Sunedison Inc, and Advaxis, Inc.

1. TWTR is 2.4% higher at $28.28, after Saudi Arabian billionaire Prince Alwaleed bin Talal and his investment company, Kingdom Holding Co., increased their stake in the social media firm. Thanks to the combined holding, Alwaleed owns more than 5% of Twitter Inc, making him the second-largest investor, per Reuters. The social media firm has been all over the news lately, after appointing Jack Dorsey as CEO. While TWTR is up 5.5% in October, the stock remains more than 20% lower year-to-date, which has caught the attention of bearish option players. The security's 50-day put/call volume ratio of 0.44 on the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) ranks higher than 96% of all readings taken in the past 52 weeks. Interestingly, 11 analysts continue to rank TWTR a "strong buy," compared to 13 "holds" and no "sells," which could leave the stock vulnerable to downgrades..

• SUNE is 7.8% higher at $9.36 -- and the stock briefly explored double-digit territory for the first time in two weeks, peaking at $10.07. Earlier this week, Sunedison Inc announced that it will cut roughly 1,000 jobs as part of a restructuring plan, and last night the firm announced that it will not complete its acquisition of Latin American Power (subscription required). This morning, SUNE trimmed its 2016 production forecast, and said it expects to be cash positive through next year. Since July's six-year high of $33.45, the shares have shed 72% -- yet analysts maintain a bullish stance. At last check, 11 of the 13 analysts tracking SUNE rate it a "buy" or better. 

• The U.S. Food and Drug Administration (FDA) announced that it was putting a clinical hold on ADXS' experimental cancer drug, following the death of a patient. Shares of Advaxis, Inc. initially fell 21.4% to $8.10, but have since battled back, paring their loss to 1.4% to sit at $10.17. Since its mid-September high of $22.20, ADXS has surrendered more than half its value beneath resistance at its 10-day moving average. While short sellers have stocked up on ADXS (30.3% of the equity's float is sold short), analysts and option players hold the firm in a bullish light. All five of the brokerages covering ADXS rate it a "strong buy," leaving quite a bit of room for momentum-killing downgrades. Furthermore, the biotech's 50-day call/put volume ratio of 5.51 on the ISE/CBOE/PHLX ranks in the 92nd percentile of its annual range. Capitulation from this bullish crew could push the shares lower still.

Get the skinny on all the biggest stories of the morning… Sign up now to get Schaeffer's Midday Market Check delivered straight to your inbox!